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Objective: Whether distal inflammation in asthmatics also leads to structural changes in the alveolar parenchyma
remains poorly examined, especially in patients with uncontrolled asthma. We hypothesized that patients who do
not respond to conventional inhaled corticosteroid therapy have a distinct tissue composition, not only in central,
but also in distal lung.
Methods: Bronchial and transbronchial biopsies from healthy controls, patients with controlled atopic and patients
with uncontrolled atopic asthma were processed for immunohistochemical analysis of fibroblasts and extracellular
matrix molecules: collagen, versican, biglycan, decorin, fibronectin, EDA-fibronectin, matrix metalloproteinase
(MMP)-9 and tissue-inhibitor of matrix metalloproteinase (TIMP)-3.
Results: In central airways we found increased percentage areas of versican and decorin in patients with
uncontrolled asthma compared to both healthy controls and patients with controlled asthma. Percentage area of
biglycan was significantly higher in both central airways and alveolar parenchyma of patients with uncontrolled
compared to controlled asthma. Ratios of MMP-9/TIMP-3 were decreased in both uncontrolled and controlled
asthma compared to healthy controls. In the alveolar parenchyma, patients with uncontrolled asthma had increased
percentage areas of collagen, versican and decorin compared to patients with controlled asthma. Patients with
uncontrolled asthma had significantly higher numbers of myofibroblasts in both central airways and alveolar
parenchyma compared to patients with controlled asthma.
Conclusions: Tissue composition differs, in both central and distal airways, between patients with uncontrolled and
controlled asthma on equivalent doses of ICS. This altered structure and possible change in tissue elasticity may
lead to abnormal mechanical properties, which could be a factor in the persistent symptoms for patients with
uncontrolled asthma.
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MyofibroblastsIntroduction
Asthma is a chronic inflammatory airway disease that is
traditionally characterized by reversible central airway
obstruction and airway hyperreactivity [1,2]. Although
treatment with bronchodilators and inhaled glucocorti-
costeroids (ICS) normally provide good control of the
disease, a significant proportion of the asthmatic patients
have persistent symptoms despite conventional therapy* Correspondence: maria.weitoft@med.lu.se
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unless otherwise stated.[3]. This phenomenon, called uncontrolled asthma [4,5],
represents a key challenge for increasing asthma control.
Little is known about the inflammatory and remodeling
processes causing persisting symptoms in this group of
asthmatics. A likely cause of these symptoms is the pres-
ence of steroid-resistant components in both central and
peripheral airways, as well as conventional inhalation ther-
apy’s insufficient ability to reach the peripheral airways [6].
The peripheral airways have an important but poorly stud-
ied role in asthma pathophysiology [7,8]. The few previous
studies that have studied transbronchial biopsies from pa-
tients with asthma provide clear indications that bothLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lular inflammation [8-10].
In an inflammatory environment such as the asthmatic
airway, fibroblasts are activated to myofibroblasts, which
deposit molecules including collagens and proteoglycans
into the surrounding extracellular matrix [11-13]. Myofi-
broblasts can be induced by a variety of factors e.g.
transforming growth factor (TGF)-β1, the alternatively
spliced domain A of fibronectin (EDA-fibronectin) as
well as mechanical force [14]. Proteoglycans have several
important functions in the tissue including storing cyto-
kines such as TGF-β1, acting as structural components
in tissue organization by forming large complexes with
hyaluronan and collagens, as well as cell signaling affect-
ing differentiation, migration and inflammation [15-17].
The matrix metalloproteinases (MMPs) are a family of pro-
teases, involved in the breakdown of extracellular matrix
[18]. A disruption in the balance between matrix produc-
tion, MMPs and their regulators tissue inhibitors of metal-
loproteinases (TIMPs) can result in changes in extracellular
matrix composition and fibrosis [19].
We have previously shown that increased collagen depos-
ition occurs in alveolar parenchyma already in patients with
mild untreated asthma [20]. However, how remodeling is
linked to clinical control of asthma remains to be investi-
gated. The aim of this study is to further advance this con-
cept by a thorough investigation of extracellular matrix
components and fibroblast densities in patients with con-
trolled asthma and uncontrolled asthma on equivalent
doses of ICS, compared to healthy controls. We hypothe-
sized that patients with uncontrolled asthma have an altered
tissue composition compared to both patients with con-
trolled asthma and healthy controls, which could be one
cause of the persistent symptoms in this group of patients.
Methods
Patient characteristics
The present study included 9 patients with controlled
atopic asthma and 16 patients with uncontrolled atopic
asthma according to GINA guidelines and asthma control
test (ACT) [4,21]. Uncontrolled asthma was defined as
still symptomatic despite treatment with ICS and beta-2
agonist (ACT score < 20). Eight healthy never-smoking
non-atopic subjects (no respiratory symptoms, normal
lung function, negative SPT and not hyper-responsive to
methacoline) were used as controls. From each of the
33 subjects, central airway biopsies and transbronchial
biopsies were collected during a study period from May
2007 to February 2012 at the Department of Respiratory
Medicine, Lund University Hospital. All subjects gave
their written informed consent to participating in the
study, which was approved by the ethics committee in
Lund (LU213-05). For details on the skin prick test, exhaled
NO measurements, sputum induction and processing,spirometry and methacoline inhalation challenge test,
see Additional file 1.
Bronchoscopy with collection of bronchial and
transbronchial biopsies and bronchoalveolar lavage
From each patient, central airway biopsy specimens (n = 5)
were taken from the segmental or subsegmental carina in
the right lower and upper lobes, followed by sampling of
transbronchial biopsy specimens (n = 5) in the right lower
lobe. In total, 330 biopsies were collected. Bronchoscopy
was performed as previously described [8]. Bronchoalveo-
lar lavage (BAL) was performed in the right middle lobe.
For details see Additional file 1.
Processing of tissue
For processing of tissue, see Additional file 1. Sections
were pre-treated and deparaffinized in an automated PT
link (Dako, Glostrup, Denmark) according to Additional
file 1: Table S2.
Immunohistochemistry
All antibodies used have been extensively validated for
staining of human tissue in research and routine clinical
diagnosis (Additional file 1: Table S2). Staining was absent
in sections using isotype-matched control antibodies
(Dako, Glostrup, Denmark). For trichrome staining, see
Additional file 1.
Immunohistochemical staining of versican, decorin,
biglycan, fibronectin, EDA-fibronectin, MMP-9 and TIMP-3
A double staining protocol (EnVision™ G|2 Doublestain
System, K5361, Dako) was used for simultaneous
visualization of versican and decorin. A single staining
protocol (EnVision™ Detection system, K5007, Dako)
was used for visualization of biglycan, fibronectin,
EDA-fibronectin, MMP-9 and TIMP-3. The immunohis-
tochemistry protocols were performed using an auto-
mated immunohistochemistry robot (Autostainer, Dako).
Sections were stained with Mayer’s haematoxylin for visu-
alisation of background tissue and mounted. For details
see Additional file 1.
Tissue analysis
Quantification of versican, decorin, biglycan, fibronectin,
EDA-fibronectin, MMP-9 and TIMP-3
Stained slides were digitally scanned using ScanScope
(Aperio, Vista, CA). All markers were quantified in blinded
sections in central airways (bronchial biopsies) and alveolar
parenchyma (transbronchial biopsies). The immunoreactiv-
ity (% positively stained area) of versican, decorin, biglycan,
fibronectin, EDA-fibronectin, MMP-9 and TIMP-3 as well
as the tissue area in the walls of bronchi and in the alveolar
septa was calculated using Visiomorph™ (Visiopharm,
Hoersholm, Denmark). The percentage stained area was











Age, years 23 [22–28] 29 [25–35] 44 [28–52]
FEV1, (L) 3.7 [3.4–5.1] 4.0 [3.3–4.8] 3.0 [2.4–4.0]
FEV1, % of
predicted
98 [91–113] 91 [86–103] 81 [72–88]
PD20, (μg) > 2000 296 [74–1143] 266 [96–531]
FeNO50, (ppb) 15 [9–17] 24 [17–36] 28 [20–48]
Bronchial NO,
(ppb)
0.75 [0.45–0.98] 1.2 [0.9–1.6] 1.4 [0.85–2.7]
Alveolar NO,
(ppb)
2.1 [2–2.5] 2.7 [1.7–3.4] 2.7 [1.8–3.5]
Atopy, yes/no 0/8 9/0 16/ 0
Rhinitis, yes/no 0/8 9/0 15/ 1
ICS/day, (μg) - 800 [400–800] 800 [400–800]
Smoking, yes/no 0/8 0/9 0/16
ACT score - 23 [22–24] 17 [13–19]
FEV1 = forced expiratory volume in 1 second, PD20 = provocative dose
(methacholine) producing a fall in FEV1 of 20 %, FeNO50 = exhaled nitric oxide,
measured at a flow rate of 50 ml ⁄ s, NO = nitric oxide, ppb = parts per billion,
ICS = inhaled glucocorticosteroids, ACT = asthma control test.
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area. The image analysis program calculated the tissue
area of the whole biopsy, excluding air spaces so that only
tissue (i.e. airway epithelium, lamina propria and smooth
muscle layer, or the alveolar septa) was measured. Glands
were excluded from the analysis by manual detection.
Quantification of myofibroblasts
The density of fibroblasts and myofibroblasts was counted
manually and calculated either as double positive for
prolyl 4-hydroxylase (P4OH) and vimentin (fibroblasts)
or triple positive for αSMA, P4OH and vimentin
(myofibroblasts). The number of cells was related to
tissue area (cells/mm2) using Visiomorph™ (Visiopharm).
For details see Additional file 1.
Immunoassay for MMP-9 in BAL and sputum
Concentration of MMP-9, in bronchoalveolar lavage (BAL)
fluid and sputum samples was measured by enzyme-linked
immunosorbent assay (ELISA) (MMP-9 ELISA DuoSet,
R&D Systems, MN, USA).
Statistical analysis
Data are presented as median values together with inter-
quartile range unless otherwise stated. Non-parametric
Mann–Whitney was used for comparison between two
groups with Bonferroni post hoc test for correction of
multiple comparisons. Correlation analysis was per-
formed using Spearman rank correlation test. Critical
p values (alpha) were adjusted according to Bonferroni.
Subsequently, alpha values of <0.017 (*), <0.0033 (**) and
<0.00033 (***) denote significant levels of difference. All
analysis was performed using GraphPad Prism version
6.0a software (GraphPad Software, San Diego USA).
Results
Demographic and clinical characteristic
An overview of patient characteristics is presented in Table 1.
Uncontrolled asthma
Two patients were treated with leukotriene-receptor an-
tagonist; three patients were treated with antihistamines
and two with nasal steroids. FEV1 % predicted was lower
in patients with uncontrolled asthma compared to healthy
controls (p = 0.018). FeNO was higher in patients with un-
controlled asthma compared to controls (p = 0.001). There
was no significant difference in alveolar NO between pa-
tients with uncontrolled asthma and controls.
Controlled asthma
There was no difference in FEV1 % predicted or exhaled
NO between healthy controls and patients with con-
trolled asthma. All asthmatics were treated with inhaled
glucocorticosteroids and inhaled bronchodilators. Allasthmatics were non-smokers although three were ex-
smokers.
Characterization of connective tissue alterations in
patients with controlled or uncontrolled asthma and
healthy controls
Increased percentage area of collagen in alveolar
parenchyma of patients with uncontrolled, but not
controlled asthma
Masson’s trichrome staining was used to examine total col-
lagen content (Figure 1). In the central airways, collagen
was seen in the subepithelial region (i.e. the lamina propria)
and reticular basement membrane (Figure 1C-E). In the
transbronchial biopsies, collagen was found in the septa of
the alveolar parenchyma (Figure 1F-H). The alveolar par-
enchyma displayed an increased percentage area of colla-
gen in patients with uncontrolled asthma compared to
healthy controls (p = 0.011), Figure 1B.
Increased percentage area of versican and decorin but not
biglycan in patients with uncontrolled asthma
In central airways, versican and decorin expression was
seen in elastic fibers in the lamina propria (Figure 2E-G).
Decorin expression was located adjacent to the reticular
basement membrane while versican predominantly was
found deeper in the airway wall closer to the smooth
muscle bundles. In the alveolar parenchyma, versican and
decorin expression was found in irregular and patchy
Figure 1 Percentage area of collagen (trichrome staining, % positively stained area) in bronchial and transbronchial biopsies from
controls and patients with controlled and uncontrolled asthma (A-B). Data are presented as scatter dot plots where horizontal line denotes
median value. Representative micrographs of tissue stained with trichrome staining (collagen: blue) from controls (C, F), controlled asthma (D, G)
and uncontrolled asthma (E, H). Scale bars: C-E, G and H = 100 μm and F = 200 μm.
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area of versican was increased in central airways in pa-
tients with uncontrolled asthma compared to both
patients with controlled asthma (p = 0.011) and healthy
controls (p = 0.0038), Figure 2A. However, in the alveolar
parenchyma there was a decreased percentage area of
versican in patients with controlled asthma compared to
healthy controls (p = 0.007), Figure 2B.
In central airways, decorin was increased in patients
with uncontrolled asthma compared to both patients
with controlled asthma (p = 0.0028) and healthy controls
(p = 0.0015), Figure 2C. In the alveolar parenchyma, per-
centage area of decorin was significantly higher in pa-
tients with uncontrolled asthma compared to healthy
controls and patients with controlled asthma (p = 0.0014
and p = 0.0067 respectively), Figure 2D.
Biglycan expression was seen in elastic fibers in the
lamina propria of the central airway wall and in irregular
and patchy areas in the alveolar septa. In central airways,
percentage area of biglycan was decreased in patients
with controlled asthma compared to patients with un-
controlled asthma (p = 0.0004), Figure 3A and C-E. The
same pattern was seen in the alveolar parenchyma,where the percentage area of biglycan was decreased in
patients with controlled asthma compared to healthy
controls and patients with uncontrolled asthma (p = 0.011
and p = 0.0017 respectively), Figure 3B and F-H.
Decreased MMP-9 and increased TIMP-3 in central airways
and alveolar parenchyma of patients with controlled and
uncontrolled asthma
Expression of MMP-9 was primarily seen in columnar
cells in the airway epithelium and in inflammatory cells
in the lamina propria and adventitia of the central
airway wall and in cells located in the alveolar septa,
Figure 4. Double immunohistochemical staining showed
that MMP-9 positive cells were mainly neutrophils, macro-
phages and scattered mast cells, Additional file 1: Figure S3.
A constitutive low intensity expression of MMP-9 was
found in both healthy controls and patients with
asthma. However, scattered strong positive epithelial
cells and inflammatory cells were predominantly found
in controls. Expression of TIMP-3 was found in the
elastic fibers of the lamina propria of the central airway
wall as well as in the matrix surrounding the smooth muscle
bundles, Figure 5A and C-E. In the alveolar parenchyma
Figure 2 Percentage area of versican (A, B) and decorin (C, D) (% positively stained area) in bronchial and transbronchial biopsies from
controls and patients with controlled and uncontrolled asthma. Data are presented as scatter dot plots where horizontal line denotes
median value. Representative micrographs of double staining of versican (brown) and decorin (red) from controls (E, H) and patients with
controlled asthma (F, I) and uncontrolled asthma (G, J) in bronchial (E-G) and transbronchial (H-J) biopsies. Scale bars: F, G = 50 μm, E, I and
J = 100 μm, H = 200 μm.
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areas in the alveolar septa, Figure 5B and F-H. The per-
centage area of MMP-9 was decreased in central airways
of patients with controlled and uncontrolled asthmacompared to healthy controls (p < 0.0001 and p = 0.0001
respectively), Figure 4A and E-C. There was also a de-
creased percentage area of MMP-9 in the alveolar pa-
renchyma of patients with controlled asthma compared
Figure 3 Percentage area of biglycan (% positively stained area) in bronchial (A) and transbronchial biopsies (B) from controls and
patients with controlled and uncontrolled asthma. Representative micrographs of staining of biglycan (brown) from controls (C, F) and
patients with controlled asthma (D, G) and uncontrolled asthma (E, H) in bronchial (C-E) and transbronchial (F-H) biopsies. Scale bars:
C-H = 50 μm.
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(p = 0.0025 and p = 0082 respectively), Figure 4B and F-H.
In central airways, there was an increased percentage
area of TIMP-3 in patients with uncontrolled asthma
compared to healthy controls (p = 0.087), Figure 5A and
C-E. There was also an increased percentage area of
TIMP-3 in the alveolar parenchyma, in both patients
with controlled and uncontrolled asthma compared to
healthy controls (p = 0.011 and p = 0.0008 respectively),
Figure 5 B and F-H. For MMP-9/TIMP-3 ratios, see
Additional file 1: Figure S3. There was no significant
difference in MMP-9 concentration in BAL or sputum
between healthy controls and patients with asthma,Additional file 1: Figure S2. For cellular profile in BAL,
see Additional file 1: Table S1.
Increased numbers of myofibroblasts in alveolar
parenchyma of patients with uncontrolled asthma
Triple positive myofibroblasts (αSMA, P4OH and vimen-
tin) were found in central airway wall, predominantly
situated just below the reticular basement membrane.
In central airways, patients with controlled asthma had
significantly fewer myofibroblasts than patients with un-
controlled asthma (p < 0.0001), Figure 6A. No difference
in myofibroblast numbers was found between patients
with uncontrolled asthma and healthy controls in the
Figure 4 Percentage area of MMP-9 (% positively stained area) in bronchial (A) and transbronchial biopsies (B) in controls and patients
with controlled and uncontrolled asthma. Representative micrographs of staining of MMP-9 (brown) from controls (C, F) and patients with
controlled asthma (D, G) and uncontrolled asthma (E, H) in bronchial (C-E) and transbronchial (F-H) biopsies. Scale bars: C-E and G = 100 μm,
F and H = 200 μm.
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the septa of the alveolar parenchyma. In the alveolar
parenchyma, patients with controlled asthma had sig-
nificantly fewer myofibroblasts than healthy controls
and patients with uncontrolled asthma (p = 0.0016 and
p < 0.0001 respectively), Figure 6B. In patients with con-
trolled asthma the number of myofibroblasts correlated
negatively with ICS-dose per day (rs = −0.75, p = 0.008).
Tendency towards increased percentage area of EDA-fibronectin
in alveolar parenchyma of patients with uncontrolled asthma
but not in patients with controlled asthma
Expression of fibronectin and EDA-fibronectin was
measured in central airways and alveolar parenchymain patients with controlled and uncontrolled asthma
and healthy controls. No difference in total fibronectin
percentage area was found between healthy controls
and asthmatics in either central airways or alveolar
parenchyma, Additional file 1: Figure S4. There was a
tendency towards increased percentage area of alterna-
tively spliced domain A of fibronectin (EDA-fibronectin)
in central airways and alveolar parenchyma, of patients
with uncontrolled asthma compared to healthy controls,
Figure 7A-H.
Discussion
This study shows that the bronchial wall and alveolar
parenchyma have an altered composition of matrix that
Figure 5 Percentage area of TIMP-3 (% positively stained area) in bronchial (A) and transbronchial biopsies (B) in controls and patients
with controlled and uncontrolled asthma. Representative micrographs of staining of TIMP-3 (brown) from controls (C, F) and patients with
controlled asthma (D, G) and uncontrolled asthma (E, H) in bronchial (C-E) and transbronchial (F-H) biopsies. Scale bars: C-E and G = 100 μm,
F and H = 200 μm.
Weitoft et al. Respiratory Research 2014, 15:67 Page 8 of 13
http://respiratory-research.com/content/15/1/67differs between patients with controlled and uncontrolled
asthma on equivalent doses of ICS, which could con-
tribute to the symptoms in patients with uncontrolled
asthma.
Due to the inaccessibility of tissue from alveolar par-
enchyma of asthmatic patients little is known regarding
the remodeling processes in the peripheral lung and how
these changes contribute to asthma pathology [20]. The
present study applied a unique study design of obtaining
bronchial as well as transbronchial biopsies from patients
with uncontrolled and controlled asthma on equivalent
doses of ICS, as well as from healthy control subjects.
Emerging new evidence show that distal airways are sub-
jected to an inflammatory process in asthmatic patients[8,10]. TGF-β1 plays a central role in airway remodeling
and has been found to induce production of several types
of collagens from myofibroblasts [22,23]. Although the pa-
tients with uncontrolled asthma had significantly thicker
reticular basement membrane [24] there was no difference
in total collagen content in central airways when measur-
ing the whole biopsy. However, expression of collagen in
distal airways was increased in uncontrolled asthmatics
but not in patients with controlled asthma, compared to
controls. Thickening of alveolar walls due to increased
amounts of collagen may lead to impaired gas exchange in
the alveoli. We have previously reported on increased col-
lagen in distal airways of patients with mild untreated
asthma [20], which raises the question if this accumulation
Figure 6 Density of myofibroblasts per tissue area (triple positive cells/mm2) in central airways (A) and alveolar parenchyma (B) from
controls and patients with controlled and uncontrolled asthma. Representative micrographs of triple staining of myofibroblasts: (C) nuclei:
Hoechts 33342, blue, (D) prolyl-4OH: Alexa F488, green, (E) vimentin: AlexaF 647, deep red, (F) α-SMA: AlexaF 555, red. Merged image are shown
in (G) where * denotes triple positive cells. High magnification image of fibroblast with protrusions are shown in (H). rbm: reticular basement
membrane and ep: airway epithelium.
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also why the patients with uncontrolled asthma have in-
creased areas of collagen despite treatment. The patients
were determined to be uncontrolled at the time when the
biopsies were taken - could an increased dose of ICS re-
verse this accumulation of collagen?
Biglycan and decorin are two small leucine-rich pro-
teoglycans involved in collagen fibrillogenesis and fibril
stabilization in the tissue [25]. Both decorin and biglycan
have been found to bind TGF-β1 in vitro [26]. However,
a study by Kolb et al. showed that, in vivo, only decorin
and not biglycan was found to interfere with TGF-β1 ac-
tivity [27]. In addition, decorin has been found to act
protective against liver fibrosis by attenuating TGF-β1
signaling [28]. In this aspect, one can speculate that theincrease in decorin expression in patients with uncon-
trolled asthma could be a protective mechanism to miti-
gate remodeling. On the other hand, increased amounts
of decorin could by regulating cross-linking and interfi-
brillar spacing create a stiffer collagen matrix, which
could affect the overall elasticity of the lung tissue. Fur-
thermore, decorin could also have a role in protecting
collagen fibrils from cleavage by collagenases, as in vitro
studies of collagenases has shown [29], which could con-
tribute to the accumulation of collagen in the tissue. While
the quantity of proteoglycan present is partly responsible
for collagen fibril morphology, variations in the glycosami-
noglycan chains have also been shown to play important
roles in e.g. collagen fibril size control and interfibrillar
spacing [30-32]. Characterization of glycosaminoglycan
Figure 7 Percentage area of EDA-fibronectin (% positively stained area) in controls and patients with uncontrolled asthma (F).
Representative micrographs of staining of EDA-fibronectin (brown) from controls (C, F) and patients with controlled asthma (D, G) and uncontrolled
asthma (E, H) in bronchial (C-E) and transbronchial (F-H) biopsies. Scale bars: C-H= 100 μm.
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and healthy individuals could provide valuable information
on the subject.
Versican is a large proteoglycan that is highly interactive
with several matrix components including hyaluronan and
fibrillin [33,34]. Increased levels of versican have been re-
ported in diseases such as atherosclerosis and cancers
[35,36]. Accumulation of versican, as seen in the central
airways of patients with uncontrolled asthma, could also
lead to increased stiffness around cells, which in turn can
influence their ability to migrate, proliferate, adhere andremodel the matrix [37]. Versican could also increase stiff-
ness in the lung by inhibiting elastin-binding proteins and
interfering with the assembly of elastic fibers, thereby
affecting lung function [38]. We can only speculate re-
garding the decreased percentage areas of biglycan and
versican in controlled asthmatics. In cultured fibroblasts
serum induced production of proteoglycans is reduced
by addition of corticosteroids [39], since the fibroblasts
used in this study are “healthy”, this could be in accord-
ance with how fibroblasts in patients with controlled
asthma respond to corticosteroids. It is possible that there
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trolled and uncontrolled asthmatics, or that the inhaled
corticosteroids do not reach the peripheral airways.
There was a decreased ratio between MMP-9 and
TIMP-3, in central and distal airways of both patient
groups, which indicates a proteolytic-antiproteolytic
imbalance. Although, since the ratio is decreased in
both patient groups it does not explain the differences
in percentage areas of matrix molecules between patients
with controlled and uncontrolled asthma. Additional ana-
lyses of other MMPs, TIMPs and their relationship with
structural alterations in the lung tissue need to be further
examined. Taken together, these structural alterations
affect phenotypes of cells and the biomechanical proper-
ties of the lung.
The fibroblasts/myofibroblasts play a pivotal role in
remodeling processes as the main extracellular matrix
producing cells. Corticosteroids have been found to pre-
vent myofibroblast accumulation and airway remodeling
in mice [40]. Interestingly, we found increased numbers
of myofibroblasts in alveolar parenchyma in patients
with uncontrolled asthma compared to healthy controls
while the number of myofibroblasts was decreased in
patients with controlled asthma compared to both controls
and patients with uncontrolled asthma. Levels of TGF-β1
mRNA as well as immunoreactivity have been found to be
increased in the airways submucosa of asthmatic patients,
with a direct correlation to the severity of the disorder
[41]. Interleukin-13 (IL-13) is another important mediator
in asthma pathogenesis, which has been associated with
tissue fibrosis, both by inducing proliferation of fibroblasts
and collagen production but also by activation of TGF-β1
[42-44].
EDA-fibronectin cooperates with TGF-β1 in modulating
fibroblasts into the activated myofibroblast phenotype
[14]. The increased amount of myofibroblasts in the al-
veolar parenchyma of patients with uncontrolled asthma
could be linked to the increased expression of EDA-
fibronectin, and is in accordance with our finding of an
increased percentage area of several matrix components
such as collagen and decorin.
The differences in myofibroblast numbers, in patients
with controlled asthma compared to uncontrolled asthma,
raises the question how the ICS treatment affects the tis-
sue and why it varies between patient groups. Could it be
due to differences in steroid-sensitivity, or does the inhal-
ation therapy not reach the peripheral airways? Indeed, in
patients with controlled asthma there was a negative cor-
relation between numbers of myofibroblasts and daily
dose of ICS, which was not found in the group of uncon-
trolled asthmatics. Although ICS has a well-documented
effect on airway inflammation, little is known regarding
long-term effects on remodeling and mesenchymal cell
growth. Effects of steroids on extracellular matrix seem todepend on the nature of the study since in vitro and
in vivo animal and human studies often show conflicting
results. This matter is further complicated by the possibility
that myofibroblasts respond differently to steroids in some
patient-groups which is concordant with the heterogeneity
of asthma.
Summary
Our study shows that tissue composition differs between
patients with controlled and uncontrolled asthma on
equivalent doses of ICS. Our data support the notion
that patients who have remaining symptoms despite
conventional ICS therapy have a pronounced matrix
remodeling in both central and distal airways and should
thus benefit from treatment strategies that target specific
inflammatory and remodeling responses in the distal lung.
The increased percentage areas of several matrix compo-
nents and myofibroblasts could be a contributing factor to
the persistent symptoms in uncontrolled asthma. Due to
the heterogeneity of the disease, asthma medicine needs
to be individualized, and new treatments for prevention of
remodeling needs to be developed. Currently, several ther-
apies directed at IL-13 are in development [45]. How
those therapies and other systemic treatments like oral
corticosteroids, Omalizumab (Anti-IgE) and Mepolizumab
(Anti-IL-5) etc. affect the inflammatory response, and
structural changes in the peripheral lung, is an important
future research area.
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